FDA Approves Essilor Stellest for Myopia Control

Here’s a breakdown of the provided text, summarizing the key information:

main Topic: FDA Authorization⁢ of Essilor Stellest Lenses for Myopia Control

Key Points:

* Positive Advancement: The ⁤FDA’s authorization of Essilor Stellest lenses is a significant and positive step for myopia management in⁢ the ⁢United States. Canada has already had access to these and other anti-myopia options.
* ⁤ Non-Invasive Option: ⁢ Stellest lenses offer an evidence-based, non-invasive choice for slowing myopia progression, particularly for ⁤children not ready for contact lenses or families preferring to avoid atropine drops.
* Personalized Care: More treatment options allow for more personalized myopia management, which is crucial given the complexity of ‍the condition.
* Growing ‍Recognition: The FDA approval highlights the increasing recognition of early intervention in pediatric eye care.
* Expanded ⁣Treatment Landscape: This announcement ⁢broadens treatment options for patients, families, and practitioners.

Author:

* ⁤ Sherman Tung, OD, OOMOMC, ICMM

* ⁢ Affiliations:

‍ * ⁢ Advisory board member, American Academy ‍of Orthokeratology and Myopia Control
* Externship preceptor, Illinois College of Optometry
⁢ * ⁣ Owner, ‍EyeLab, Vancouver, British Columbia
*‍ Disclosures: Reports financial relationships with Hoya, coopervision, and 3N Eyecare.

Source:

* ⁢ FDA Press Release: https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia?utm_medium=email&utm_source=govdelivery

additional Disclosure:

* The⁤ author of the article (not Sherman Tung) reports no relevant financial disclosures.

Publisher: Primary Care Optometry News (healio.com)